Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.58, $0.04 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.55 billion.

GUIDANCE:

Edwards Lifesciences sees Q1 2026 EPS of $0.70-$0.76, versus the consensus of $0.69. Edwards Lifesciences sees Q1 2026 revenue of $1.55-1.63 billion, versus the consensus of $1.57 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.